Related Experiment Video
Updated: Nov 15, 2025
10:28
Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease
Published on: July 24, 2019
15.7K
Digital Therapeutics in Parkinson's Disease: Practical Applications and Future Potential
Terry D Ellis1, Gammon M Earhart2
1Department of Physical Therapy & Athletic Training, Center for Neurorehabilitation, College of Health and Rehabilitation Sciences: Sargent College, Boston University, Boston, MA, USA.
Journal of Parkinson'S Disease
|March 1, 2021
Summary
Digital therapeutics offer personalized Parkinson's disease management remotely. Despite their potential, especially during the COVID-19 pandemic, these technologies remain underutilized.
Area of Science:
- Neurology
- Digital Health
- Rehabilitation Medicine
Background:
- Parkinson's disease (PD) presents complex management challenges.
- The COVID-19 pandemic highlighted the need for remote healthcare solutions.
- Digital therapeutics (DTx) offer a promising avenue for PD management.
Purpose of the Study:
- To review current applications of DTx for Parkinson's disease.
- To explore emerging advances in DTx platforms for PD.
- To discuss future potential and barriers to DTx adoption in PD care.
Main Methods:
- Literature review of digital therapeutic platforms for Parkinson's disease.
- Analysis of emerging technologies targeting motor and non-motor symptoms.
- Discussion of lifestyle interventions integrated into DTx.
Main Results:
- DTx platforms can target motor and non-motor symptoms of Parkinson's disease.
- Emerging advances focus on personalized, evidence-based interventions.
- Healthy lifestyle behaviors (diet, exercise, sleep) are increasingly incorporated.
Conclusions:
- Digital therapeutics hold significant potential for transforming Parkinson's disease self-management and patient care.
- Despite advancements and increased interest, DTx for PD are underdeveloped and underutilized.
- Addressing barriers to access is crucial for widespread adoption and realizing the full benefits of DTx in Parkinson's disease management.
Related Concept Videos
01:24Parkinson's Disease: Treatment
740
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
740
01:15Parkinson's Disease: Overview
1.2K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.2K
01:28Drug Therapy
153
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
153
01:29Therapeutic Drug Monitoring: Affecting Factors
69
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
69
01:21EPS and iPS Cells in Disease Research
3.1K
Embryonic and induced pluripotent stem cells are excellent models for disease research because of their ability to self-renew and differentiate into most cell types. Somatic cells from a patient are isolated and reprogrammed into induced pluripotent stem cells or iPSCs. These iPSCs are later differentiated into the desired cell type, which mirrors the diseased cell of the patient. In this way, disease models have been created for investigating diseases such as Down syndrome, type I diabetes,...
3.1K
01:22Alzheimer's Disease: Treatment
565
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
565